Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
Key Highlights
- ➤Voyager will present VY1706 first-in-human study design at CTAD 2026
- ➤VY1706 is a systemic, blood-brain barrier-penetrant tau-lowering gene therapy
- ➤Voyager will present VY7523 multiple-ascending-dose study baseline characteristics
- ➤VY7523 is a clinical-stage monoclonal antibody targeting tau’s C-terminal region
Expert Statements
Elena Ratti, VP, Clinical Development at Voyager Therapeutics
“VP, Clinical Development”
LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place in Boston, November 16-19, 2026. The poster presentations will highlight VY1706, Voyager’s investigational gene therapy designed to lower tau production in the brain, and VY7523, the Company’s clinical stage monoclonal antibody directed against the C-terminal region of tau.
CLINICAL TRIALS – PHASE I & IIA First-in-human study design of VY1706, a systemically administered blood-brain barrier (BBB)-penetrant tau lowering gene therapy in early Alzheimer’s disease (#P055). Elena Ratti, M.D., MMSc, VP, Clinical Development. Monday, November 16, 2026, 2:00 p.m. - Tuesday, November 17, 2026, 5:30 p.m. ET
Get started
Create a free account to read the full story.